Table 2.

Multivariate analysis of outcomes in pre-diabetic and diabetic NAFLD

	Relative to non-diabetic NAFLD				Relative to non-diabetic non-NAFLD
	Diabetes		Pre-diabetes		Diabetes		Pre-diabetes
	Effect size	P-value	Effect size	P-value	Effect size	P-value	Effect size	P-value
CVD	RR, 1.90 (95% CI, 1.64 to 2.21)	<0.01*	RR, 1.20 (95% CI, 1.03 to 1.41)	0.02*	RR, 1.85 (95% CI, 1.63 to 2.10)	<0.01*	RR, 1.18 (95% CI, 1.03 to 1.35)	0.02*
Stroke	RR, 1.66 (95% CI, 1.29 to 2.15)	<0.01*	RR, 0.89 (95% CI, 0.69 to 1.66)	0.41	RR, 1.35 (95% CI, 1.26 to 1.43)	<0.01*	RR, 0.98 (95% CI, 0.91 to 1.05)	0.61
CKD	RR, 1.47 (95% CI, 1.10 to 1.97)	0.01*	RR, 0.93 (95% CI, 0.81 to 1.09)	0.41	RR, 1.82 (95% CI, 1.60 to 2.08)	<0.01*	RR, 1.17 (95% CI, 1.01 to 1.36)	0.04*
CVD mortality	SHR, 1.41 (95% CI, 1.02 to 1.94)	0.04*	SHR, 1.11 (95% CI, 0.82 to 1.52)	0.49	SHR, 1.30 (95% CI, 0.99 to 1.71)	0.06	SHR, 1.00 (95% CI, 0.77 to 1.31)	0.99
Overall mortality	HR, 1.60 (95% CI, 1.38 to 1.85)	<0.01*	HR, 1.14 (95% CI, 0.99 to 1.34)	0.06	HR, 1.35 (95% CI, 1.19 to 1.52)	<0.01*	HR, 0.98 (95% CI, 0.87 to 1.10)	0.98

NAFLD, nonalcoholic fatty liver disease; CVD, cardiovascular disease; RR, risk ratio; CI, confidence interval; CKD, chronic kidney disease; SHR, sub-distribution hazard ratio; HR, hazard ratio.

^*P-value ≤0.05 denotes statistical significance.